Clinical trialNACompleted
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (<70gy vs. >70Gy) in Locally Advanced Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 10 November 2020
- Expected end
- 15 August 2025
- Enrollment
- 119 participants
- Sites
- 2
- Primary outcomes
- Progression-Free-Survival
- Sponsor
- Other
- Results posted
- 2025-10-20
- Last update
- 20 October 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (\<70Gy Vs.\>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-Free-Survival [3 years]. Median, month (95% Confidence Interval). Arm A (n=60): 8.6 (7.5 to 9.6); Arm B (n=59): 11.3 (10.1 to 12.5).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Adverse Events [3 years]. Count Of Participants, Participants. Arm A (n=60): 58; Arm B (n=59): 57.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [3 years]. Median, months (95% Confidence Interval). Arm A (n=60): 12.2 (10.9 to 13.5); Arm B (n=59): 17.2 (15.4 to 19.0).